一种新型 BRAF 抑制剂打破了抗药性障碍。

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-07-01 Epub Date: 2024-06-11 DOI:10.1016/j.trecan.2024.05.009

Morena Scotece, Matthias Drosten

引用次数: 0

摘要

由于疾病复发，已批准的 BRAF 抑制剂临床疗效有限。在最近的一篇《癌症发现》（Cancer Discovery）论文中，Yaeger 等人指出，新一代 BRAF 抑制剂 PF-07799933 在实验模型和对已批准的 BRAF 抑制剂治疗无效的患者中具有广泛的治疗活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A new BRAF inhibitor breaks resistance barriers.

Approved BRAF inhibitors have shown limited clinical benefit due to recurrent disease progression. In a recent Cancer Discovery paper, Yaeger et al. show that a next-generation BRAF inhibitor, PF-07799933, has widespread therapeutic activity in experimental models and patients who were refractory to treatment with approved BRAF inhibitors.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.